Synthetic biologists.
Immunologists.
Data scientists.

Together, we’re making designer mRNA drugs to cure serious illnesses.

Drugs that leverage our immune system rather than work against it. Drugs that are more accessible to more people. Drugs that put humans first.

Team

Yusuf Erkul

Yusuf Erkul MD, MBA

Chief Executive Officer & Cofounder

Physician entrepreneur who developed an FDA-approved cancer drug at Merck & Co
Burak Yilmaz

Burak Yilmaz MS

President & Cofounder

Serial entrepreneur and synthetic biologist who founded his first biotech company at age 22
Manfred Kraus

Manfred Kraus PhD

VP, Head of R&D Therapeutics
Firat Ileri

Firat Ileri

Board Member
Pablo Lubroth

Pablo Lubroth MPhil

Board Observer
Gladys Nunez

Gladys Nunez

Board Observer
Matthew Strout

Matthew Strout MD, PhD

VP of Business Development
Stephen DiPalma

Stephen DiPalma MBA

Chief Financial Officer
Balkrishen Bhat

Balkrishen Bhat PhD

Head of LNP Formulation
Cafer Ozdemir

Cafer Ozdemir PhD

Director of Convergence Science & Cofounder
Ryan Landis

Ryan Landis PhD

Principal Scientist / LNP Formulation
Yulia Rybakova

Yulia Rybakova PhD

Senior Research Scientist
Kelly Brock

Kelly Brock

Senior Computational Biologist
Jieni Xu

Jieni Xu PhD, PMP

Senior Scientist, LNP Formulation
Rudy Christmas

Rudy Christmas

Scientist II , Immuno Oncology
Pedro Rivera Pomales

Pedro Rivera Pomales

Process Development Scientist
Isaak Mueller

Isaak Mueller PhD

Scientist, Synthetic Biology
Maxwell Alexander

Maxwell Alexander MS

Data Scientist, Computational Biology
Sadik Yildiz

Sadik Yildiz PhD

Data Scientist, Computational Biology
Tom Addison

Tom Addison

Senior Associate Scientist, Synthetic Biology
Leona Lee

Leona Lee MS

Research Associate II, Synthetic Biology
Mark Krimmer

Mark Krimmer

Research Associate, LNP Formulation

Advisory
Board

Arthur Krieg

Arthur Krieg MD

Clinical Advisor, Nucleic Acid Therapeutics

Founder / CEO / CSO of 4 successful nucleic acid companies
Edward Benz Jr

Edward Benz Jr MD

Clinical Advisor, Medical Oncology

President & CEO Emeritus of Dana Farber Cancer Institute, Harvard Medical School
Peter <br>Blume-Jensen

Peter
Blume-Jensen MD, PhD

Clinical Advisor, Cancer Drug Development

CEO of Acrivon Therapeutics and former Head of Oncology at of Merck
Nikolai Slavov

Nikolai Slavov PhD

Scientfic Advisor, mRNA Translation

Associate Professor, Northeastern University
Dean <br>Felsher

Dean
Felsher MD, PhD

Clinical Advisor, Translational Oncology

Director of Stanford Medicine Translational Research & Applied Medicine at Stanford Medical School
Dan Peer

Dan Peer PhD

Scientific Advisor

Vice President for R&D, Tel Aviv University

This
could
be you.

Careers